Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 16:4:38.
doi: 10.1186/1746-1596-4-38.

CD10 expression in urothelial carcinoma of the bladder

Burak Bahadir  1 , Kemal Behzatoglu, Sibel Bektas, Erol R Bozkurt, Sukru O Ozdamar
Affiliations

CD10 expression in urothelial carcinoma of the bladder

Burak Bahadir et al. Diagn Pathol. .

Abstract

Background: CD10 antigen is a 100-kDa-cell surface zinc metalloendopeptidase and it is expressed in a variety of normal and neoplastic lymphoid and nonlymphoid tissues. The aim of this study was to evaluate CD10 expression in urothelial carcinoma of the urinary bladder and to determine the correlation between immunohistochemical (IHC) CD10 expression and histopathologic parameters including grade and stage.

Methods: 371 cases of urothelial bladder carcinomas, all from transurethral resections, were included in this study. Hematoxylin-eosin (HE) stained sections from each case were reevaluated histopathologically according to WHO 2004 grading system. The TNM system was used for pathologic staging. Selected slides were also studied by IHC and a semiquantitative scoring for CD10 expression based on the percentage of positive cells was performed.

Results: 157 cases (42.3%) showed immunostaining while 214 cases (57.7%) were negative for CD10. 1+ staining was seen in 65 CD10 positive cases (41.4%), and 2+ in 92 cases (58.6%). Overall CD10 expression as well as 2+ immunostaining was significantly correlated with high histologic grade. Overall CD10 expression was also significantly higher in invasive pT1 and pT2-3 tumors compared to noninvasive pTa tumors. pT1 and pT2-3 tumors were also significantly correlated with 2+ immunostaining.

Conclusion: To date, only a few comparative IHC studies have assessed CD10 expression in urothelial carcinoma of the urinary bladder and this study represents the largest series. Our findings indicate that CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder, and that CD10 may be associated with tumor progression in bladder cancer pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Noninvasive (pTa) papillary urothelial carcinoma demonstrating strong (thick arrows) and weak (thin arrows) CD10 immunostaining.
Figure 2
Figure 2
Another example of noninvasive (pTa) papillary urothelial carcinoma showing strong CD10 expression.
Figure 3
Figure 3
CD10 expression in invasive (pT1) papillary urothelial carcinoma. Intense staining corresponds to cells with high grade histology (arrows).
Figure 4
Figure 4
Diffuse CD10 immunostaining in invasive (pT2) urothelial carcinoma. Membranous and cytoplasmic staining is best appreciated in the inset.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Torti FM, Lum BL. The biology and treatment of superficial bladder cancer. J Clin Oncol. 1984;2:505–31. - PubMed
    1. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol. 1998;160:1668–1671. doi: 10.1016/S0022-5347(01)62377-2. discussion 1671-1672. - DOI - PubMed
    1. Huland H, Otto U, Droese M, Klöppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol. 1984;132:27–29. - PubMed
    1. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993;329:1377–1382. doi: 10.1056/NEJM199311043291903. - DOI - PubMed